Calciu-D3 Masticabil

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Calciu-D3 Masticabil

Property Description
Active ingredient Calcium Carbonate, Dihydrotachysterol
Form Chewable Tablets (Comprimate Masticabile)
Pharmacological Class Mineral Supplements, Vitamin D Analogs, Bone Density Conservation Agent
Common Use Supporting mineral homeostasis and bone health
Origin Fixed combination of naturally occurring mineral salt and synthetic analogue

Defining Calciu-D3 Masticabil and its Classification

Calciu-D3 Masticabil is a fixed-dose combination product administered via the oral route as a Chewable Tablet (Masticabile). It is broadly classified as a Mineral Supplement and a Bone Density Conservation Agent. This combination is engineered to simultaneously supply essential minerals and enhance the body's natural capacity for mineral absorption and regulation.

The designation as a Bone Density Conservation Agent reflects its established role in supportive therapy for maintaining skeletal integrity. The physical form of a chewable tablet is often favored for patient groups, such as the elderly, who require an easily consumable format for sustained daily supplementation.


Composition and Purpose

The core composition includes two active ingredients: Calcium Carbonate and Dihydrotachysterol. Calcium Carbonate serves as the primary source of the essential mineral, providing elemental calcium (Ca^2+). Dihydrotachysterol, on the other hand, is a synthetic analogue of Vitamin D that facilitates the optimal utilization of the mineral.

The general purpose of Calciu-D3 Masticabil is to support mineral homeostasis and the conservation of bone density. This analogue enhances the intestinal absorption of calcium and aids in regulating mineral levels in the bloodstream, providing a comprehensive approach to addressing mineral deficiencies.

Regulatory References

  1. NIH Fact Sheet for Health Professionals on Calcium
Advertisements

What side effects are possible with Calciu-D3 Masticabil?

Possible Side Effects and Safety Information

The officially documented safety profile for this medicine, which combines Calcium Carbonate and a potent Vitamin D analogue (Dihydrotachysterol), is primarily defined by the risk of hypercalcemia (abnormally high blood calcium levels).

Adverse Reaction Scope

Adverse reactions are classified in regulatory documents according to the organ system affected, which helps categorize potential risks.

System-Organ Class Examples of Documented Adverse Reactions
Metabolism & Nutrition Hypercalcemia, Hypercalciuria, Anorexia, Weight loss
Gastrointestinal Constipation (often noted as common or expected), Nausea, Vomiting
Renal & Urinary Polyuria (increased urination), Nephrocalcinosis, Irreversible renal insufficiency
Vascular & Systemic Hypertension, Generalized vascular calcification, Weakness

Serious Adverse Reactions and Safety Patterns

The serious adverse reactions documented in official labels are generally consequences of sustained, severe hypercalcemia. These include outcomes such as irreversible renal insufficiency and generalized vascular calcification of soft tissues. The potential for a severe increase in calcium levels that can lead to a hypercalcemic crisis is also officially noted.

Regulatory documents state that the pharmacological effects of the Vitamin D analogue component, particularly toxicity, can persist for two or more months following the discontinuation of the medicine, which is a key safety pattern.

Safety Restrictions and Special Populations

Safety restrictions officially contraindicate the use of this medicine in patients with pre-existing conditions such as hypercalcemia, hypervitaminosis D, and malabsorption syndrome. For patients with renal impairment, official labeling emphasizes the necessity of closely maintaining normal serum phosphorus levels to mitigate the risk of metastatic calcification. Furthermore, the regulatory documents note that in pediatric patients, there is a risk of decline in the average rate of linear growth.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Calciu-D3 Masticabil, a combination of Calcium Carbonate and Dihydrotachysterol, is primarily associated with Hypervitaminosis D and resulting Hypercalcemia, according to official regulatory documentation. All overdose information is strictly derived from government-approved labeling and does not constitute medical advice.


Documented Manifestations and Severe Outcomes

Initial overdose presentations documented in prescribing information include non-specific systemic symptoms such as anorexia, nausea, vomiting, fatigue, headache, polyuria (increased urination), and polydipsia (increased thirst). Laboratory findings typically involve Hypercalcemia and Hypercalciuria. Severe or life-threatening outcomes officially listed include renal failure, nephrocalcinosis, and cardiac arrhythmias.


Regulatory Actions and Management

Immediate withdrawal of the product is required upon identifying an overdose. Regulatory sources explicitly state that management is symptomatic and supportive, as no specific antidote is known. Procedures for severe cases may involve intravenous saline infusion, administration of diuretics and corticosteroids, and gastric lavage for recent ingestion. Hospital monitoring, including serial monitoring of serum calcium and renal function tests, is generally required.


When Immediate Medical Help is Required

Immediate medical attention must be sought for any suspicion of overdose or if severe symptoms such as uneven heartbeats, high fever, or a sudden change in mental status occur. Official guidance mandates contacting emergency services for these life-threatening events.

Advertisements

Therapeutic Uses of Calciu-D3 Masticabil

What Calciu-D3 Masticabil Treats: Main Uses and Benefits

The therapeutic application of Calciu-D3 Masticabil is relevant for managing symptoms related to systemic imbalance and providing supportive relief for skeletal integrity. Vitamin D and calcium are relevant components for supporting strong bones and managing conditions associated with their deficiency.

This product is commonly used to help manage conditions involving episodic or fluctuating manifestations such as osteoporosis and osteomalacia, and may assist with managing symptoms related to hypocalcemia and Rickets in appropriate patient groups. It is applied across domains where additional symptomatic support is needed, primarily to support general well-being during symptomatic phases. The use of this product contributes to easing the overall symptom load and supports the management of symptoms related to physical discomfort like muscle cramps.

“This product is relevant for managing conditions presenting with systemic or localized discomfort associated with low bone mass.”

Quick Fact: Relief for Skeletal Support

The use of this combination is primarily relevant for patients, including older adults and postmenopausal women, who may face accelerated mineral loss or inadequate absorption, and may assist with maintaining functional stability.

Regulatory References

  1. NIH Office of Dietary Supplements
Advertisements

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Calciu-D3 Masticabil (Calcium Carbonate and Colecalciferol), as defined by regulatory documents.

Contraindications (Who Must Not Use)

Use of this medicine is absolutely prohibited for patients with the following conditions:

Condition
Hypercalcaemia (high blood calcium levels)
Severe Hypercalciuria (excessive urinary calcium)
Hypervitaminosis D (Vitamin D overdose)
Severe Renal Impairment or Failure
Nephrolithiasis (kidney stones) or Nephrocalcinosis
Known Hypersensitivity to the active substances or excipients

Age and Special Population Eligibility

Population Regulatory Status
Children under 12 years Not Recommended (Safety and efficacy not established).
Adults and Elderly Use is generally established.
Pregnancy/Lactation Use must be under the direction of a physician; overdose must be strictly avoided.
Mild to Moderate Renal Impairment Requires caution and monitoring of calcium levels.
Sarcoidosis Requires caution and monitoring due to increased Vitamin D sensitivity.

The official eligibility profile is structured by these contraindications and conditional use requirements, defining who is formally excluded from using the medicine based on pre-existing clinical state, organ function, and age limitations.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Calciu-D3 Masticabil is structured around pharmacokinetic interference and additive pharmacodynamic effects, based on the two active ingredients.

Timing and Absorption Interference

The Calcium Carbonate component interferes with the absorption of several co-administered oral medicines due to chelation. A mandatory dose separation is required with agents such as Oral Bisphosphonates, Tetracycline Antibiotics, Fluoroquinolone Antibiotics, and Thyroid Hormones to prevent reduced systemic exposure of the co-administered agent. For example, Bisphosphonates must be separated by at least 30 minutes. Furthermore, Gastric Acid Reducing Agents may reduce the absorption of the Calcium Carbonate component.

Pharmacodynamic and Exposure Alterations

The Dihydrotachysterol component's exposure may be increased by strong CYP3A4 inhibitors or decreased by drugs like Bile Acid Sequestrants. Co-administration with Cardiac Glycosides (e.g., Digoxin) is associated with an officially documented increased risk of ventricular arrhythmias due to additive effects on serum calcium. Thiazide Diuretics are associated with an increased risk of hypercalcemia by interfering with calcium excretion.

Dietary and Population Notes

The absorption of elemental calcium is documented to be reduced by Foods high in Oxalic Acid (e.g., spinach) or Phytic Acid (e.g., whole grains). A high intake of Vitamin D or Calcium supplements has an additive effect, increasing the regulatory risk of toxicity. Official documents note that Hepatic Impairment or co-existing Hyperphosphatemia may heighten the risk or severity of these interactions.

Advertisements

Mechanism of Action

Upon ingestion, calcium carbonate is solubilized in the gastric environment, releasing calcium ions ( Ca^2+).

These ions are absorbed across the intestinal epithelium via transcellular active transport and paracellular passive diffusion.

Cholecalciferol (Vitamin D3) undergoes hydroxylation in the liver and kidney to form the active metabolite, calcitriol (1,25-dihydroxycholecalciferol). Calcitriol binds to the Vitamin D Receptor (VDR), a nuclear transcription factor, upregulating the expression of key intestinal calcium transport proteins (e.g., TRPV6 and calbindin D9k).

This process enhances the net flux of calcium ions from the intestinal lumen into the systemic circulation. Systemic calcium ions ( Ca^2+) are required for osteoblast-mediated matrix mineralization and hydroxyapatite formation within the bone structure. The combined effect supports homeostatic maintenance of plasma calcium concentration by modulating intestinal absorption, renal excretion, and bone turnover.

Advertisements

Dosage and Administration Information

How to Use Calciu-D3 Masticabil

The administration of Calciu-D3 Masticabil follows protocols defining the proper route, schedule, and conditions of intake for this fixed-dose combination product.


Official Administration Guidelines

Feature Guideline
Route of Administration The medicine is approved strictly for oral administration.
Dosing Schedule Standard regimens typically call for one or two tablets daily for supportive use.
Preparation Method As a Chewable Tablet (Masticabil), the tablet must be chewed or sucked completely before being swallowed; it is not to be ingested whole.
Timing Relative to Meals Administration is often instructed to be taken with or immediately after a meal to enhance the absorption of the calcium carbonate component.

Procedural Conditions and Use Patterns

Special Procedural Constraints:

Administration must be separated in time from certain co-administered oral medications, such as tetracyclines, bisphosphonates, and levothyroxine, by a minimum of two to four hours. This procedural constraint is essential to prevent the calcium component from interfering with the absorption of other drugs.

Long-Term Use and Adjustment:

The product is intended for long-term use or continuous supplementation to maintain mineral homeostasis. Due to the high potency of the Dihydrotachysterol component, the protocol for use requires periodic laboratory monitoring of serum calcium and urinary calcium levels. This continuous evaluation guides the prescriber in determining and maintaining the correct dose over the course of treatment.

Population Guidelines:

Patients with renal impairment require individualized dosage adjustment; its use may be restricted or contraindicated in cases of severe impairment to manage the risks associated with altered vitamin D metabolism. The standard adult dosing regimen is typically followed for older adults.

Advertisements

Recent Clinical Evidence

Evidence for Supportive Therapy in Bone and Mineral Deficiencies

Research has explored calcium combined with a specific Vitamin D analogue in conditions such as Osteoporosis and Osteomalacia. Studies include Randomized Controlled Trials (RCTs) and Meta-analyses that have examined new fracture rates and changes in Bone Mineral Density (BMD). Findings describe patterns observed in the studies where the combination was evaluated in comparison with placebo or calcium alone. Evidence is limited because comparative evidence is lacking for this specific analogue against some standard treatments, and findings were mixed when comparing institutionalized older adults versus community-dwelling populations.


Evidence for Management of Hypocalcemia and Renal/Glandular Dysfunction

The combination was studied for conditions such as Hypoparathyroidism and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). This research utilized Clinical Trials and long-term observational data to monitor biochemical outcomes like serum calcium and Parathyroid Hormone (PTH) levels. The analogue was observed in short-term comparative trials that monitored serum mineral levels. Sample sizes were modest in these specialized studies, meaning evidence quality varies across studies. Data are still emerging regarding the long-term risk of developing renal complications like nephrocalcinosis associated with sustained use.


Evidence Gaps and Long-Term Research

Research has examined long-term outcomes for fracture incidence in meta-analyses that have tracked data up to seven years. However, long-term effects are not fully established for patient-centered outcomes such as quality of life. Data for certain groups remain insufficient, including specific subgroup findings for older adults and children in the context of CKD. The evidence highlights what is known — and what is still uncertain due to inconsistent findings and a reliance on surrogate biochemical markers.

Key Studies & References

  1. Vitamin D and Calcium: A Systematic Review of Health Outcomes (Agency for Healthcare Research and Quality)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calciu-D3 Masticabil (FAQ)


Q: Does Calciu-D3 Masticabil contain sugar or artificial sweeteners?

A: The official product literature (SmPC) provides a complete list of all non-active ingredients, known as excipients. To confirm the presence of specific substances like lactose, sugar, or artificial sweeteners in the chewable tablet, it is necessary to check the full regulatory document for the specific product formulation.


Q: Can Calciu-D3 Masticabil be taken with other vitamins?

A: The regulatory guidance indicates the importance of consulting a healthcare provider before combining the medicine with other vitamins or supplements. This is primarily because combining it with additional Vitamin D or calcium could lead to an additive effect, potentially increasing the official regulatory risk of toxicity.


Q: Is it normal to feel slightly nauseous after taking Calciu-D3 Masticabil?

A: Regulatory documents note nausea as a documented gastrointestinal adverse reaction associated with the medicine. Official sources indicate that this effect is generally classified as rare, but it is a known possibility reported in the safety profile.


Q: What should I do if I notice a change in my urine color while taking Calciu-D3 Masticabil?

A: While regulatory documents specifically list polyuria (increased frequency of urination), safety information notes that certain changes in urine quality, such as foamy or cloudy urine, may occur. These types of changes are noted in safety information as potential signs that may require medical evaluation.


Q: Is sun exposure still necessary when taking Calciu-D3 Masticabil?

A: Vitamin D is naturally synthesized by the skin through exposure to the sun. The medicine is officially intended to provide supplementation when the body’s necessary requirements for Vitamin D and calcium are not met through diet or lifestyle factors, such as limited time in the sun.


Q: Can I crush Calciu-D3 Masticabil and mix it with food if I have trouble chewing?

A: The product is explicitly designed to be a chewable tablet that must be chewed or sucked completely before being swallowed. Official instructions define the required preparation method and do not include guidance for crushing and mixing the tablet with food.


Q: Does the efficacy of Calciu-D3 Masticabil change if I take it with or without food?

A: Official instructions recommend taking the medicine with or immediately after a meal. This procedural condition is defined to enhance the absorption and bioavailability of the calcium carbonate component of the medicine.


Q: Are there specific food types that interact with Calciu-D3 Masticabil?

A: Regulatory documents note that food components such as Oxalic Acid (found in spinach and rhubarb) and Phytic Acid (found in whole grains) may reduce calcium absorption. Consumption of Grapefruit or its juice may also alter the exposure of the Vitamin D analogue component.


Q: Does Calciu-D3 Masticabil affect weight gain or loss?

A: The official safety profile includes anorexia (loss of appetite) and weight loss as documented adverse reactions. These effects are generally associated with potentially elevated levels of calcium in the blood.


Q: Is Calciu-D3 Masticabil suitable for people with lactose intolerance?

A: The full regulatory document (SmPC) provides the complete list of non-active ingredients (excipients) used in the chewable tablet. It is necessary to review this official list to confirm if lactose is present in the formulation.


Q: What happens if I forget to take a dose of Calciu-D3 Masticabil?

A: Official guidance usually recommends taking a missed dose as soon as it is remembered. If it is already nearly time for the next scheduled dose, the patient should skip the missed dose and continue with the regular schedule. Regulatory guidance specifies that taking two doses at the same time is not recommended.


Q: How long can I continue taking Calciu-D3 Masticabil?

A: The medicine is intended for long-term use or continuous supplementation to maintain mineral homeostasis. Regulatory protocols define the need for periodic laboratory monitoring of serum and urinary calcium levels to guide the appropriate dose over the course of treatment.


Q: Can I take Calciu-D3 Masticabil if I have high blood pressure?

A: Regulatory documents list hypertension (high blood pressure) as a potential vascular adverse reaction. Regulatory documents indicate that patients with pre-existing high blood pressure may require monitoring to evaluate the medicine's effect.


Q: Does Calciu-D3 Masticabil interact with common antibiotics?

A: Yes, the calcium component is officially documented to interact with specific classes of antibiotics, notably Tetracycline Antibiotics and Fluoroquinolone Antibiotics. This requires mandatory separation of administration times to prevent reduced antibiotic absorption.


Q: Is Calciu-D3 Masticabil available over the counter?

A: The commercial status (Over-the-Counter or Prescription) depends on the specific strength and formulation of the Vitamin D analogue component. Some high-potency Vitamin D analogues and dosages are only available by prescription due to the risk of toxicity and the necessity of medical monitoring.


Q: Why is it important not to take certain iron supplements with Calciu-D3 Masticabil?

A: The calcium component of the medicine is officially documented to interfere with the absorption of certain iron supplements. Regulatory guidance indicates that administration times should be separated by at least two hours to help support the effectiveness of the iron supplement.


Q: Is Calciu-D3 Masticabil used for osteoporosis prevention or just treatment?

A: Regulatory documents describe the medicine's role as a Bone Density Conservation Agent in the supportive therapy for conditions such as osteoporosis. Its components are also officially documented for the treatment and prevention of calcium and Vitamin D deficiency states.


Q: What is the general duration of effect after taking one dose of Calciu-D3 Masticabil?

A: Official safety documents emphasize that due to the potent nature of the Vitamin D analogue, the pharmacological effects, particularly concerning elevated calcium levels, can persist for two or more months after the medicine is stopped.


Q: Are there any known interactions with herbal supplements and Calciu-D3 Masticabil?

A: Official guidance indicates the importance of consulting with a healthcare professional before combining the medicine with any other supplements, including herbal products. This is the standard procedure to ensure no unforeseen interactions or additive effects occur.


Q: Why do some people need a calcium and D3 combination product instead of just one?

A: Regulatory and scientific documents explain that the combination is used because the Vitamin D analogue component is necessary to facilitate and enhance the intestinal absorption of the calcium component. This combined effect supports the body's overall mineral homeostasis.


Q: Is Calciu-D3 Masticabil safe to take if I'm already taking medicine for thyroid issues?

A: The medicine's calcium component is documented to interfere with the absorption of certain thyroid hormone replacement medications. A mandatory separation of administration times, typically by at least four hours, is required to avoid reduced effectiveness of the thyroid medicine.


Q: Do I need a blood test to confirm I need Calciu-D3 Masticabil?

A: The medicine has strict contraindications, such as pre-existing hypercalcaemia (high blood calcium levels), which is typically determined through blood tests. Furthermore, the protocol requires periodic laboratory monitoring of serum and urinary calcium levels while on the medicine.


Q: Is there evidence that Calciu-D3 Masticabil helps with muscle cramps?

A: Official documents describe the medicine's role in helping the body maintain adequate calcium levels, which are required for proper muscle and nerve function. Low calcium levels in the blood are officially associated with symptoms such as muscle cramps, pain, and twitching.


Q: Do any official documents discuss the benefits of Calciu-D3 Masticabil for specific bone density issues?

A: Research evidence themes documented in official sources cover the use of the medicine's components for conditions such as Osteoporosis and Osteomalacia, which involve bone density issues. These studies examine outcomes like changes in Bone Mineral Density.


Q: Do any studies suggest the effectiveness of Calciu-D3 Masticabil depends on age?

A: Official summaries of research evidence note that studies have examined population subgroups, including a comparison of outcomes between older adults in institutional care and those living in the community. The evidence indicates that mixed findings were reported across these different age-related groups.


Q: Are there any major drug categories that interact with Calciu-D3 Masticabil?

A: Yes, major categories of interacting medicines are documented in official sources. These include Cardiac Glycosides (increased risk of arrhythmias), certain Antibiotics (reduced absorption), Thiazide Diuretics (risk of hypercalcemia), and Thyroid Hormone replacements (reduced absorption).

Advertisements

How should Calciu-D3 Masticabil be stored and disposed of?

How to Store and Dispose of Calciu-D3 Masticabil?

The storage and disposal of Calciu-D3 Masticabil (Calcium Carbonate, Dihydrotachysterol chewable tablets) must strictly adhere to regulatory requirements to maintain product stability and ensure environmental safety.


Storage Conditions

  • Temperature and Protection: Store the medicine at room temperature and do not store above 25 C or 30 C, depending on the specific formulation. The tablets must be protected from light and moisture.
  • Container Rules: Always keep the product in the original container or carton. If the product is in a bottle, the container must be kept tightly closed.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

  • Environmental Rule: Do not dispose of unused or expired medicine via wastewater (flushing) or household waste.
  • Recommended Action: Consult the pharmacist for instructions on how to properly throw away medicines no longer required, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calciu-D3 Masticabil found in:

A-Z Index: